You can buy or sell Opiant and other stocks, options, ETFs, and crypto commission-free!
Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. It focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Read More Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. Opiant Pharmaceuticals was founded on June 21, 2005 and is headquartered in Santa Monica, CA.
Santa Monica, California
52 Week High
52 Week Low
Yahoo FinanceMay 13
OPNT: Encouraging Pharmacokinetic Data for OPNT003…
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Financial Update On May 9, 2019, Opiant (OPNT) announced financial results for the first quarter of 2019. The company recorded a total of $5.4 million in revenue for the three months ending Mar. 31, 2019, which consisted of $3.7 million in royalty revenue from the sale of NARCAN® Nasal Spray, $1.6 million of grant and contract revenue, and $0.08 million from treatment investment revenue. This compares to royalty revenue of $1.6 m...
Seeking AlphaMay 13
Opiant Pharmaceuticals, Inc. CEO Roger Crystal on Q1 2019 Results - Earnings Call Transcript
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Roger Crystal - CEO David O'Toole - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald David Bautz - Zacks Investment Research Operator Greetings, and welcome to the Opiant Pharmaceuticals First Quarter 2019 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasur...
Yahoo FinanceMay 9
Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the three months ended March 31, 2019, and provided a corporate update. “We continue to advance our addiction and drug overdose-focused pipeline, and are committed to validating the data in peer-reviewed journals,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Cl...
Expected Aug 8, After Hours